TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Smith & Nephew Snats ( (SNN) ) is now available.
Smith & Nephew plc announced on November 19, 2025, that key executives participated in the company’s Employee Stock Purchase Plan, acquiring American Depositary Shares through the Dividend Re-Investment Plan after the interim dividend payment on November 7, 2025. This transaction, conducted on the New York Stock Exchange, underscores the company’s commitment to aligning managerial interests with shareholder value, potentially enhancing stakeholder confidence.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc operates in the medical technology industry, focusing on the development and manufacturing of advanced medical devices. The company is known for its products in orthopaedics, sports medicine, and wound management, with a strong market presence in these areas.
Average Trading Volume: 642,447
Technical Sentiment Signal: Buy
Current Market Cap: $13.86B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.